LEO Pharma, PellePharm form $760m rare skin disease collaboration
LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
This decision vacates the District Court’s preliminary injunction that had prohibited Dr. Reddy’s from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result
In the trail, the clinical-stage biotechnology company will evaluate uproleselan in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin). Both
The submission is supported by a paediatric open-label study conducted in children aged six to 11 years that investigated pharmacokinetics, pharmacodynamics and long-term safety. Mepolizumab, a humanised anti-IL5
Nexus Pharmaceuticals chief commercial officer Omair Ahmed said: “The approval of generic Arsenic Trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables.